Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 6/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.37 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL706462 | 0.89 | SLC18A3 (0.44) | GNAO1SLC18A3CHRM2CHRM4CHRM5 | |
| SCHEMBL23423411 | 0.88 | GNAO1 (0.58) | GNAO1ITGB3ITGA2BGNAI3GNAI1 | |
| SCHEMBL8054785 | 0.83 | CHRM2 (0.46) | GNAO1SLC18A3CHRM2CHRM4CHRM5 | |
| SCHEMBL16079060 | 0.82 | GNAO1 (0.69) | GNAO1ITGB3ITGA2BGNAI3GNAI1 | |
| SCHEMBL25843607 | 0.81 | NCF1 (0.42) | GNAO1GNAI3GNAI1SLC18A3CHRM2 | |
| SCHEMBL7287283 | 0.80 | ITGB3 (0.65) | GNAO1ITGB3ITGA2BGNAI3GNAI1 | |
| SCHEMBL19040043 | 0.79 | GNAO1 (0.60) | GNAO1ITGB3ITGA2BGNAI3GNAI1 | |
| SCHEMBL12324733 | 0.79 | ITGB3 (0.52) | GNAO1ITGB3ITGA2BGNAI3GNAI1 | |
| SCHEMBL31129716 | 0.79 | GNAO1 (0.51) | GNAO1ITGB3ITGA2BGNAI3GNAI1 | |
| SCHEMBL1318049 | 0.78 | SLC18A3 (0.46) | GNAO1SLC18A3CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7279470-B2 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2007-10-09 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7067517-B2 | Use of compounds for decreasing activity of hormone-sensitive lipase | NERO NORDISK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| WO-2005113542-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| EP-1458375-A2 | COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| EP-1458374-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| WO-2003051841-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051842-A2 | COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
| US-6042987-A | FOR PLANOGRAPHIC PRINTING PLATE, IMAGE RECORDING LAYER CONTAINS A HEAT OR LIGHT DEGRADABLE COMPOUND WHICH GENERATES AN ACID; CURING AGENT WHICH CROSSLINKS IN PRESENCE OF ACID, ALKALI SOLUBLE RESIN; IR ABSORBER; AND AMINO ACID | FUJI PHOTO FILM CO., LTD (JP) | 2000-03-28 | — | — | US | disclosed |
| US-4384083-A | POLYURETHANE, POLYESTER, POLYAMIDE | APPLIED POLYMER TECHNOLOGY, INCORPORATED (US) | 1983-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | LIPE, PNLIP, LPL | GNAO1 2414/4885ITGB3 4684/4885ITGA2B 4792/4885 |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | LIPE, PNLIP, LPL | GNAO1 2297/4885ITGB3 4696/4885ITGA2B 4786/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | GNAO1 739/4885ITGB3 1459/4885ITGA2B 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.